Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, FACP, Michael L. Wang, MD, Jon E. Arnason, MD, Amitkumar Mehta, MD, Enkhtsetseg Purev, MD PhD, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, Scott R. Solomon, MD, Nilanjan Ghosh, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Ana Kostic, Daniel Li, PhD, Yeonhee Kim, Tanya Siddiqi, MD

Blood (2019) 134 (Supplement_1): 241.

https://doi.org/10.1182/blood-2019-127508

Published: 2019

Journal Articles

Risks and Benefits of Bronchoscopy during the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation

Mehrdad Hefazi, MD, Reona Sakemura, MD PhD, Saad S. Kenderian, MD, Mrinal M Patnaik, MDMBBS, William J Hogan, MB, BCh, Mark Litzow, MD, Hemang Yadav, MBBS

Blood (2019) 134 (Supplement_1): 4500.

https://doi.org/10.1182/blood-2019-132133

Published: 2019

Journal Articles

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Robert Henderson, MD, Mary R Cahill, MD, Philip Murphy, MD, Vitaliy Mykytiv, MD, John Quinn, MD PhD, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Andres Hernando, Grace Hirakata, Imelda Parker, Emma Kinsella, Grainne Gannon, Alessandro Natoni, PhD, Michael E O'Dwyer, MD

Blood (2018) 132 (Supplement 1): 3242.

https://doi.org/10.1182/blood-2018-99-112375

Published: 2018

Journal Articles

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

David G. Maloney, MD PhD, Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, MD, Andres Forero, MD, Tina Albertson, MD, Jacob Garcia, MD, Daniel Li, PhD, Benhuai Xie, PhD, Tanya Siddiqi, MD

Blood (2017) 130 (Supplement 1): 1552.

https://doi.org/10.1182/blood.V130.Suppl_1.1552.1552

Published: 2017

Journal Articles

Examining the Role of Bronchoscopy in Patients with Hematological Malignancies

Nakul Singhal, MD, Rashi Sharma, MD, Ashwin Chandar, MD, Vincent McAuliffe, MD, Dennis L Cooper, MD

Blood (2016) 128 (22): 2412.

https://doi.org/10.1182/blood.V128.22.2412.2412

Published: 2016

Journal Articles

Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL

Wyndham H. Wilson, MD PhD, Leslie L. Popplewell, MD, Tycel Phillips, MD, Amy S. Kimball, MD PhD, Saurabh Chhabra, MD, Jerry Ping, PhD, Jutta Neuenburg, MD, Nora Cavazos, MD, Louis M Staudt, MD, Sven de Vos, MD PhD

Blood (2015) 126 (23): 1527.

https://doi.org/10.1182/blood.V126.23.1527.1527

Published: 2015

Journal Articles

Lung Damage and Thrombocytopenia

Mo Yang, PhD, En Yu Liang, Li Xia Zhou, Beng H Chong, PhD, Chunfu Li, MD

Blood (2015) 126 (23): 4638.

https://doi.org/10.1182/blood.V126.23.4638.4638

Published: 2015

Journal Articles

Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Bortezomib (B) in Patients (pts) with Relapsed Multiple Myeloma (MM): A Phase I/II Study in Japan.

Kensei Tobinai, MD, Takashi Watanabe, MD, Yoshiaki Ogawa, MD, Michinori Ogura, MD, Yasuo Morishima, MD, Hironobu Minami, MD, Kuniaki Itoh, MD, Tomomitsu Hotta, MD

Blood (2006) 108 (11): 5106.

https://doi.org/10.1182/blood.V108.11.5106.5106

Published: 2006

Journal Articles

High Resolution Computed Tomography of Bleomycin-Induced Lung Injury in Hodgkin Lymphoma.

Meltem Olga Akay, MD, Ragip Ozkan, MD, Dondu Uskudar, MD, Zafer Gulbas, MD.

Blood (2005) 106 (11): 4757.

https://doi.org/10.1182/blood.V106.11.4757.4757

Published: 2005

Journal Articles

Lung Damage May Induce Thrombocytopenia.

Mo Yang, PhD, Da Wei Xiao, MD, Karen Kwai Har Li, PhD, Chi Kong Li, MD, Ki Wai Chik, MBBS, Tai Fai Fok, MD

Blood (2004) 104 (11): 3026.

https://doi.org/10.1182/blood.V104.11.3026.3026

Published: 2004

NARROW

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Risks and Benefits of Bronchoscopy during the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

Examining the Role of Bronchoscopy in Patients with Hematological Malignancies

Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL

Lung Damage and Thrombocytopenia

Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Bortezomib (B) in Patients (pts) with Relapsed Multiple Myeloma (MM): A Phase I/II Study in Japan.

High Resolution Computed Tomography of Bleomycin-Induced Lung Injury in Hodgkin Lymphoma.

Lung Damage May Induce Thrombocytopenia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only